PIKing the right isoform: The emergent role of the p110β subunit in breast cancer

Virchows Archiv

Volumn 456, Issue 3, 2010, Pages 235-243

  Carvalho, Silvia ^a,b   Milanezi, Fernanda ^a,b   Costa, José Luís ^a   Amendoeira, Isabel ^c   Schmitt, Fernando ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Breast cancer; HER2; P110 ; P110 ; PI3K

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE P110ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE P110BETA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; UNCLASSIFIED DRUG; ONCOPROTEIN; PIK3CA PROTEIN, HUMAN; PIK3CB PROTEIN, HUMAN; PROTEIN SUBUNIT; PTEN PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM; DISTANT METASTASIS; ENZYME SUBUNIT; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; ONSET AGE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY; TUMOR VOLUME; AGED; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; PROTEIN MICROARRAY; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; AGED; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; ONCOGENE PROTEIN V-AKT; PROGNOSIS; PROTEIN ARRAY ANALYSIS; PROTEIN SUBUNITS; PTEN PHOSPHOHYDROLASE; TUMOR MARKERS, BIOLOGICAL;

EID: 77949716267     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-010-0881-0     Document Type: Article

References (37)

1. JA Engelman J Luo LC Cantley 2006 The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism Nat Rev Genet 7 606 619 10.1038/nrg1879 1:CAS:528:DC%2BD28XmvFCnu7Y%3D 16847462 (Pubitemid 44100518)
2. LC Cantley 2002 The phosphoinositide 3-kinase pathway Science 296 1655 1657 10.1126/science.296.5573.1655 1:CAS:528:DC%2BD38XktlChu7s%3D 12040186 (Pubitemid 34579158)
3. MP Wymann M Zvelebil M Laffargue 2003 Phosphoinositide 3-kinase signalling-which way to target Trends Pharmacol Sci 24 366 376 10.1016/S0165-6147(03)00163-9 1:CAS:528:DC%2BD3sXltl2gtL8%3D 12871670 (Pubitemid 37315529)
4. AG Bader S Kang L Zhao, et al. 2005 Oncogenic PI3K deregulates transcription and translation Nat Rev Cancer 5 921 929 10.1038/nrc1753 1:CAS:528:DC%2BD2MXht1ykurbF 16341083 (Pubitemid 41766781)
5. TL Yuan LC Cantley 2008 PI3K pathway alterations in cancer: variations on a theme Oncogene 27 5497 5510 10.1038/onc.2008.245 1:CAS:528:DC%2BD1cXhtFWiurzI 18794884
6. JA Engelman 2009 Targeting PI3K signalling in cancer: opportunities, challenges and limitations Nat Rev Cancer 9 550 562 10.1038/nrc2664 1:CAS:528:DC%2BD1MXovFylsrg%3D 19629070
7. S Di Cosimo J Baselga 2008 Targeted therapies in breast cancer: where are we now Eur J Cancer 44 2781 2790 10.1016/j.ejca.2008.09.026 19013786
8. S Klein A Levitzki 2009 Targeting the EGFR and the PKB pathway in cancer Curr Opin Cell Biol 21 185 193 10.1016/j.ceb.2008.12.006 1:CAS:528: DC%2BD1MXksVClu74%3D 19216065
9. L Shayesteh Y Lu WL Kuo, et al. 1999 PIK3CA is implicated as an oncogene in ovarian cancer Nat Genet 21 99 102 10.1038/5042 1:CAS:528: DyaK1MXltlWjtw%3D%3D 9916799 (Pubitemid 29036292)
10. A Racz N Brass D Heckel, et al. 1999 Expression analysis of genes at 3q26-q27 involved in frequent amplification in squamous cell lung carcinoma Eur J Cancer 35 641 646 10.1016/S0959-8049(98)00419-5 1:CAS:528:DyaK1MXjtVGmsb4%3D 10492640 (Pubitemid 29192975)
11. RJ Crowder C Phommaly Y Tao, et al. 2009 PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer Cancer Res 69 3955 3962 10.1158/0008-5472.CAN- 08-4450 1:CAS:528:DC%2BD1MXltFOksbo%3D 19366795
12. Y Samuels K Ericson 2006 Oncogenic PI3K and its role in cancer Curr Opin Oncol 18 77 82 10.1097/01.cco.0000198021.99347.b9 1:CAS:528:DC%2BD2MXhtlahu73P 16357568 (Pubitemid 43740454)
13. M Cully H You AJ Levine, et al. 2006 Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis Nat Rev Cancer 6 184 192 10.1038/nrc1819 1:CAS:528:DC%2BD28Xhslelt78%3D 16453012 (Pubitemid 43292562)
14. I Vivanco CL Sawyers 2002 The phosphatidylinositol 3-Kinase AKT pathway in human cancer Nat Rev Cancer 2 489 501 10.1038/nrc839 1:CAS:528: DC%2BD38XkvFKltLs%3D 12094235 (Pubitemid 37328931)
15. MP Wymann R Marone 2005 Phosphoinositide 3-kinase in disease: timing, location, and scaffolding Curr Opin Cell Biol 17 141 149 10.1016/j.ceb.2005.02. 011 1:CAS:528:DC%2BD2MXisVCqtb4%3D 15780590 (Pubitemid 40380937)
16. C Garcia-Echeverria WR Sellers 2008 Drug discovery approaches targeting the PI3K/Akt pathway in cancer Oncogene 27 5511 5526 10.1038/onc.2008.246 1:CAS:528:DC%2BD1cXhtFWiur3J 18794885
17. B Karakas KE Bachman BH Park 2006 Mutation of the PIK3CA oncogene in human cancers Br J Cancer 94 455 459 10.1038/sj.bjc.6602970 1:CAS:528: DC%2BD28Xhs1ers70%3D 16449998 (Pubitemid 43289745)
18. E Lerma L Catasus A Gallardo, et al. 2008 Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas Virchows Arch 453 133 139 10.1007/s00428-008-0643-4 1:CAS:528:DC%2BD1cXps1ahs78%3D 18679714
19. LH Saal K Holm M Maurer, et al. 2005 PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma Cancer Res 65 2554 2559 10.1158/0008-5472- CAN-04-3913 1:CAS:528:DC%2BD2MXjtVeqsrc%3D 15805248 (Pubitemid 40490050)
20. JJ Zhao Z Liu L Wang, et al. 2005 The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells Proc Natl Acad Sci U S A 102 18443 18448 10.1073/pnas. 0508988102 1:CAS:528:DC%2BD28Xpt1Gq 16339315 (Pubitemid 43011245)
21. E Ciraolo M Iezzi R Marone, et al. 2008 Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development Sci Signal 1 ra3 10.1126/scisignal.1161577 18780892
22. S Jia Z Liu S Zhang, et al. 2008 Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis Nature 454 776 779 1:CAS:528:DC%2BD1cXps1Snu7w%3D 18594509
23. R Marone V Cmiljanovic B Giese, et al. 2008 Targeting phosphoinositide 3-kinase: moving towards therapy Biochim Biophys Acta 1784 159 185 1:CAS:528:DC%2BD1cXptlerug%3D%3D 17997386
24. I Matos R Dufloth M Alvarenga, et al. 2005 p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas Virchows Arch 447 688 694 10.1007/s00428-005-0010-7 1:CAS:528:DC%2BD2MXhtFKqt7zM 16012853 (Pubitemid 41571183)
25. J Paredes N Lopes F Milanezi, et al. 2007 P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ Virchows Arch 450 73 80 10.1007/s00428-006-0334-y 1:CAS:528:DC%2BD2sXitlGjs70%3D 17123107 (Pubitemid 46360747)
26. IG Campbell SE Russell DY Choong, et al. 2004 Mutation of the PIK3CA gene in ovarian and breast cancer Cancer Res 64 7678 7681 10.1158/0008-5472.CAN-04- 2933 1:CAS:528:DC%2BD2cXptFemtbk%3D 15520168 (Pubitemid 39446895)
27. KE Bachman P Argani Y Samuels, et al. 2004 The PIK3CA gene is mutated with high frequency in human breast cancers Cancer Biol Ther 3 772 775 1:CAS:528:DC%2BD2MXhslKrtbw%3D 15254419 (Pubitemid 41351083)
28. L Zhao PK Vogt 2008 Class I PI3K in oncogenic cellular transformation Oncogene 27 5486 5496 10.1038/onc.2008.244 1:CAS:528:DC%2BD1cXhtFWiur%2FP 18794883
29. S Kang A Denley B Vanhaesebroeck, et al. 2006 Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase Proc Natl Acad Sci U S A 103 1289 1294 10.1073/pnas.0510772103 1:CAS:528:DC%2BD28Xhs1Ggurs%3D 16432180 (Pubitemid 43191158)
30. PK Vogt AG Bader S Kang 2006 Phosphoinositide 3-kinase: from viral oncoprotein to drug target Virology 344 131 138 10.1016/j.virol.2005.09.027 1:CAS:528:DC%2BD2MXhtlCqtbzL 16364744 (Pubitemid 41814457)
31. NE Hynes HA Lane 2005 ERBB receptors and cancer: the complexity of targeted inhibitors Nat Rev Cancer 5 341 354 10.1038/nrc1609 1:CAS:528:DC%2BD2MXjslertb0%3D 15864276 (Pubitemid 40637826)
32. K Kalinsky LM Jacks A Heguy, et al. 2009 PIK3CA mutation associates with improved outcome in breast cancer Clin Cancer Res 15 5049 5059 10.1158/1078-0432.CCR-09-0632 1:CAS:528:DC%2BD1MXpvFeis78%3D 19671852
33. BT Hennessy DL Smith PT Ram, et al. 2005 Exploiting the PI3K/AKT pathway for cancer drug discovery Nat Rev Drug Discov 4 988 1004 10.1038/nrd1902 1:CAS:528:DC%2BD2MXht1yktbjI 16341064
34. S Wee D Wiederschain SM Maira, et al. 2008 PTEN-deficient cancers depend on PIK3CB Proc Natl Acad Sci U S A 105 13057 13062 10.1073/pnas.0802655105 1:CAS:528:DC%2BD1cXhtFSitbrO 18755892
35. T Kirkegaard CJ Witton LM McGlynn, et al. 2005 AKT activation predicts outcome in breast cancer patients treated with tamoxifen J Pathol 207 139 146 10.1002/path.1829 1:CAS:528:DC%2BD2MXhtFKnsr7P 16088978 (Pubitemid 41404144)
36. N Maruyama Y Miyoshi T Taguchi, et al. 2007 Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women Clin Cancer Res 13 408 414 10.1158/1078-0432.CCR-06-0267 1:CAS:528:DC%2BD2sXoslSmtg%3D%3D 17202311 (Pubitemid 46225343)
37. J Baselga V Semiglazov P van Dam, et al. 2009 Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer J Clin Oncol 27 2630 2637 10.1200/JCO.2008.18.8391 1:CAS:528:DC%2BD1MXnslWit7s%3D 19380449